Researchers at Harvard Medical School have shown that statin use reduced 28-day mortality in patients hospitalized due to COVID-19. Both the new initiation of statins and continuing statin therapy reduced the risk of mortality.
The study findings have been published on a preprint server. The study was conducted as a single-center cohort involving 1179 hospitalized COVID-19 patients. Overall, 360 patients never took statins, 311 were newly initiated on a statin, 466 continued taking statins, and 42 had a statin discontinued.
The most common drug used was atorvastatin before and during hospitalization. The study findings showed that 13.1 percent of the patients died by 28 days. The team also found that using statins reduced the hazard of 28-day mortality.
Also, both the new initiation of stations and continuing statin use reduced the risk of death from COVID-19 within 28 days. The researchers noted that the reasons why statins effectively reduce mortality in COVID-19 patients include endothelial stabilization and their effect on inflammation. Giving statins during admission, even for a short duration, could positively impact the cardiovascular system. COVID-19 causes a hyperinflammatory response that triggers cardiovascular disorders.
Also, the drug’s ability to control and inhibit hydroxymethylglutaryl-coenzyme A reductase is another reason to consider. This may interfere with the virus’s ability to invade and infect cells. The team also revealed the link between statin use and mortality benefit in adults who are more than 65 years, but not in patients 65 years or younger. Since statins may help reduce mortality in COVID-19 patients, clinical trials should be performed to determine the drug’s safety.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here